Causality Discovery with Domain Knowledge for Drug-Drug Interactions Discovery

被引:3
|
作者
Subpaiboonkit, Sitthichoke [1 ]
Li, Xue [1 ,2 ]
Zhao, Xin [1 ]
Scells, Harrisen [1 ]
Zuccon, Guido [1 ]
机构
[1] Univ Queensland, Brisbane, Qld, Australia
[2] Neusoft Univ Informat, Dalian, Peoples R China
关键词
Causality discovery; Bayesian network; Drug-drug interaction;
D O I
10.1007/978-3-030-35231-8_46
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Bayesian Network Probabilistic Graphs have recently been applied to the problem of discovery drug-drug interactions, i.e., the identification of drugs that, when consumed together, produce an unwanted side effect. These methods have the advantage of being explainable: the cause of the interaction is made explicit. However, they suffer from two intrinsic problems: (1) the high time-complexity for computing causation, i.e., exponential; and (2) the difficult identification of causality directions, i.e., it is difficult to identify in drug-drug interactions databases whether a drug causes an adverse effect - or vice versa, an adverse effect causes a drug consumption. While solutions for addressing the causality direction identification exist, e.g., the CARD method, these assume statistical independence between drug pairs considered for interaction: real data often does not satisfy this condition. In this paper, we propose a novel causality discovery algorithm for drug-drug interactions that goes beyond these limitations: Domain-knowledge-driven Causality Discovery (DCD). In DCD, a knowledge base that contains known drug-side effect pairs is used to prime a greedy drugdrug interaction algorithm that detects the drugs that, when consumed together, cause a side effect. This algorithm resolves the drug-drug interaction discovery problem in O(n(2)) time and provides the causal direction of combined causes and their effect, without resorting to assuming statistical independence of drugs intake. Comprehensive experiments on realworld and synthetic datasets show the proposed method is more effective and efficient than current state-of-the-art solutions, while also addressing a number of drawbacks of current solutions, including the high time complexity, and the strong assumptions regarding real-world data that are often violated.
引用
收藏
页码:632 / 647
页数:16
相关论文
共 50 条
  • [1] Development of an ADME and drug-drug interactions knowledge database for the acceleration of drug discovery and development
    Petitet, Francois
    Barberan, Olivier
    Dubus, Elodie
    Ijjaali, Ismail
    Donlan, Mary
    Ollivier, Sophie
    Michel, Andre
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (07) : 737 - 751
  • [2] DISCOVERY AND EXPLANATION OF DRUG-DRUG INTERACTIONS VIA TEXT MINING
    Percha, Bethany
    Garten, Yael
    Altman, Russ B.
    [J]. PACIFIC SYMPOSIUM ON BIOCOMPUTING 2012, 2012, : 410 - 421
  • [3] Causality Discovery Based on Combined Causes and Multiple Causes in Drug-Drug Interaction
    Subpaiboonkit, Sitthichoke
    Li, Xue
    Zhao, Xin
    Zuccon, Guido
    [J]. ADVANCED DATA MINING AND APPLICATIONS (ADMA 2022), PT I, 2022, 13725 : 53 - 66
  • [4] Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface
    Dodd, Stephanie
    Kollipara, Sivacharan
    Sanchez-Felix, Manuel
    Kim, Hyungchul
    Meng, Qingshuo
    Beato, Stefania
    Heimbach, Tycho
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 87 - 101
  • [5] A Semantic Knowledge-Base Approach to Drug-Drug Interaction Discovery
    Tripodi, Ignacio
    Cohen, Kevin B.
    Hunter, Lawrence E.
    [J]. 2017 IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE (BIBM), 2017, : 1123 - 1126
  • [6] Predicting and where drug-drug interactions in drug discovery: Where are we now are we going?
    Hutzler, JM
    Messing, DM
    Wienkers, LC
    [J]. CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (01) : 51 - 58
  • [7] Translational Knowledge Discovery Between Drug Interactions and Pharmacogenetics
    Wu, Heng-Yi
    Shendre, Aditi
    Zhang, Shijun
    Zhang, Pengyue
    Wang, Lei
    Zeruesenay, Desta
    Rocha, Luis M.
    Shatkay, Hagit
    Quinney, Sara K.
    Ning, Xia
    Li, Lang
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (04) : 886 - 902
  • [8] Risk assessment of drug-drug interactions using hepatocytes suspended in serum during the drug discovery process
    Kosugi, Yohei
    Hirabayashi, Hideki
    Igari, Tomoko
    Fujioka, Yasushi
    Okuda, Teruaki
    Moriwaki, Toshiya
    [J]. XENOBIOTICA, 2014, 44 (04) : 336 - 344
  • [9] Evaluation of drug interactions with P-glycoprotein in drug discovery:: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein
    Hochman, JH
    Yamazaki, M
    Ohe, T
    Lin, JH
    [J]. CURRENT DRUG METABOLISM, 2002, 3 (03) : 257 - 273
  • [10] A NEW KNOWLEDGE STRUCTURE FOR DRUG-DRUG INTERACTIONS
    KUPERMAN, GJ
    BATES, DW
    TEICH, JM
    SCHNEIDER, JR
    CHEIMAN, D
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 1994, : 836 - 840